Le cellule emopoietiche progenitrici CD34+

Translated title of the contribution: CD34+ hematopoietic progenitor cells

G. D'Arena, M. Carotenuto

Research output: Contribution to journalArticle

Abstract

Although the CD34 molecule is expressed on virtually all haemopoietic progenitors, including multipotent stem cells, its function within haemopoiesis is still unknown. The CD34+ cell population is extremely heterogeneous in surface antigenic expression and these cells can be detected in bone marrow as well as in human umbilical cord blood and peripheral blood. Marked increases of circulating CD34+ cells occur during the recovery phase after myelosuppressive chemotherapy and/or growth factor administration. These cells, which can be estimated by flow cytometry, collected on a large scale by leucapheresis and cryopreserved for transplantation, are able to reconstitute haemopoiesis after myeloablative therapy. Peripheral blood haematopoietic progenitor transplantation is increasingly used for treating several malignancies such as leukaemia, lymphoma, myeloma or solid tumors. In fact, peripheral haematopoietic progenitor cell transplant usually provides earlier neutrophil and platelet recovery, less need for blood products and parenteral antibiotics and shorter hospitalization than bone marrow rescue. The restricted expression of CD34+ to haemopoietic stem/progenitor cells has been used for transplantation studies. Several techniques have been developed to select cells expressing CD34+ from haemopoietic tissues. Alternatively, CD34+ cells may be expanded in vitro by incubation with synergistic cytokine combinations before being reinfused. Finally an intriguing new development has been the use of purified populations of CD34+ cells as targets for gene therapy protocols.

Original languageItalian
Pages (from-to)66-76
Number of pages11
JournalTrasfusione del Sangue
Volume43
Issue number2
Publication statusPublished - 1998

Fingerprint

Hematopoietic Stem Cells
Transplantation
Stem Cells
Bone Marrow
Multipotent Stem Cells
Fetal Blood
Genetic Therapy
Population
Lymphoma
Neoplasms
Intercellular Signaling Peptides and Proteins
Flow Cytometry
Leukemia
Hospitalization
Neutrophils
Blood Platelets
Cytokines
Anti-Bacterial Agents
Transplants
Drug Therapy

ASJC Scopus subject areas

  • Hematology
  • Immunology and Allergy

Cite this

Le cellule emopoietiche progenitrici CD34+. / D'Arena, G.; Carotenuto, M.

In: Trasfusione del Sangue, Vol. 43, No. 2, 1998, p. 66-76.

Research output: Contribution to journalArticle

D'Arena, G & Carotenuto, M 1998, 'Le cellule emopoietiche progenitrici CD34+', Trasfusione del Sangue, vol. 43, no. 2, pp. 66-76.
D'Arena, G. ; Carotenuto, M. / Le cellule emopoietiche progenitrici CD34+. In: Trasfusione del Sangue. 1998 ; Vol. 43, No. 2. pp. 66-76.
@article{921ef41f59da444fb47665375596cc92,
title = "Le cellule emopoietiche progenitrici CD34+",
abstract = "Although the CD34 molecule is expressed on virtually all haemopoietic progenitors, including multipotent stem cells, its function within haemopoiesis is still unknown. The CD34+ cell population is extremely heterogeneous in surface antigenic expression and these cells can be detected in bone marrow as well as in human umbilical cord blood and peripheral blood. Marked increases of circulating CD34+ cells occur during the recovery phase after myelosuppressive chemotherapy and/or growth factor administration. These cells, which can be estimated by flow cytometry, collected on a large scale by leucapheresis and cryopreserved for transplantation, are able to reconstitute haemopoiesis after myeloablative therapy. Peripheral blood haematopoietic progenitor transplantation is increasingly used for treating several malignancies such as leukaemia, lymphoma, myeloma or solid tumors. In fact, peripheral haematopoietic progenitor cell transplant usually provides earlier neutrophil and platelet recovery, less need for blood products and parenteral antibiotics and shorter hospitalization than bone marrow rescue. The restricted expression of CD34+ to haemopoietic stem/progenitor cells has been used for transplantation studies. Several techniques have been developed to select cells expressing CD34+ from haemopoietic tissues. Alternatively, CD34+ cells may be expanded in vitro by incubation with synergistic cytokine combinations before being reinfused. Finally an intriguing new development has been the use of purified populations of CD34+ cells as targets for gene therapy protocols.",
keywords = "CD34+ cells, Haematopoietic progenitor cells",
author = "G. D'Arena and M. Carotenuto",
year = "1998",
language = "Italian",
volume = "43",
pages = "66--76",
journal = "Trasfusione del Sangue",
issn = "0041-1787",
publisher = "SIMTI Servizi",
number = "2",

}

TY - JOUR

T1 - Le cellule emopoietiche progenitrici CD34+

AU - D'Arena, G.

AU - Carotenuto, M.

PY - 1998

Y1 - 1998

N2 - Although the CD34 molecule is expressed on virtually all haemopoietic progenitors, including multipotent stem cells, its function within haemopoiesis is still unknown. The CD34+ cell population is extremely heterogeneous in surface antigenic expression and these cells can be detected in bone marrow as well as in human umbilical cord blood and peripheral blood. Marked increases of circulating CD34+ cells occur during the recovery phase after myelosuppressive chemotherapy and/or growth factor administration. These cells, which can be estimated by flow cytometry, collected on a large scale by leucapheresis and cryopreserved for transplantation, are able to reconstitute haemopoiesis after myeloablative therapy. Peripheral blood haematopoietic progenitor transplantation is increasingly used for treating several malignancies such as leukaemia, lymphoma, myeloma or solid tumors. In fact, peripheral haematopoietic progenitor cell transplant usually provides earlier neutrophil and platelet recovery, less need for blood products and parenteral antibiotics and shorter hospitalization than bone marrow rescue. The restricted expression of CD34+ to haemopoietic stem/progenitor cells has been used for transplantation studies. Several techniques have been developed to select cells expressing CD34+ from haemopoietic tissues. Alternatively, CD34+ cells may be expanded in vitro by incubation with synergistic cytokine combinations before being reinfused. Finally an intriguing new development has been the use of purified populations of CD34+ cells as targets for gene therapy protocols.

AB - Although the CD34 molecule is expressed on virtually all haemopoietic progenitors, including multipotent stem cells, its function within haemopoiesis is still unknown. The CD34+ cell population is extremely heterogeneous in surface antigenic expression and these cells can be detected in bone marrow as well as in human umbilical cord blood and peripheral blood. Marked increases of circulating CD34+ cells occur during the recovery phase after myelosuppressive chemotherapy and/or growth factor administration. These cells, which can be estimated by flow cytometry, collected on a large scale by leucapheresis and cryopreserved for transplantation, are able to reconstitute haemopoiesis after myeloablative therapy. Peripheral blood haematopoietic progenitor transplantation is increasingly used for treating several malignancies such as leukaemia, lymphoma, myeloma or solid tumors. In fact, peripheral haematopoietic progenitor cell transplant usually provides earlier neutrophil and platelet recovery, less need for blood products and parenteral antibiotics and shorter hospitalization than bone marrow rescue. The restricted expression of CD34+ to haemopoietic stem/progenitor cells has been used for transplantation studies. Several techniques have been developed to select cells expressing CD34+ from haemopoietic tissues. Alternatively, CD34+ cells may be expanded in vitro by incubation with synergistic cytokine combinations before being reinfused. Finally an intriguing new development has been the use of purified populations of CD34+ cells as targets for gene therapy protocols.

KW - CD34+ cells

KW - Haematopoietic progenitor cells

UR - http://www.scopus.com/inward/record.url?scp=0031816087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031816087&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0031816087

VL - 43

SP - 66

EP - 76

JO - Trasfusione del Sangue

JF - Trasfusione del Sangue

SN - 0041-1787

IS - 2

ER -